Immunological Comparison of AIT and SCIT Immunotherapy Against Grass Pollen

• Status: Completed
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Treatment of pollen allergies can be roughly divided into symptomatic treatment (e.g. antihistamines, steroids) and potentially curative immunotherapy. Immunotherapy can be delivered using subcutaneous or oral (mucosal) routes, with similar clinical outcome. The study seeks to compare immunological changes during subcutaneous (SCIT) and sublingual tablet (AIT) immunotherapy of grass pollen allergy (hayfever).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bispebjerg Hospital
• Collaborator: ALK-Abelló A/S

Criteria

Inclusion Criteria:

• history of rhinitis with hay fever symptoms during the grass pollen season,

• a skin-prick-test-verified grass pollen allergy (Phleum pratense),

• eligibility for immunotherapy based on ARIA guidelines

Exclusion Criteria:

• current long-term systemic steroid treatment,

• previous immunotherapy,

• asthma and outside-season airway hyperresponsiveness (AHR) (September 2011),

• pregnancy,

• negative RAST for grass, and

• treatment side effect